PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33588721-7 2021 RESULTS: An association between the SNPs of some risk genes and the efficacy of an antipsychotic treatment is reported: SNPs such as rs165599 (COMT gene), rs1801028 (D2 receptor gene) and rsSer9Gly (D3 receptor gene) are associated with a better antipsychotic treatment efficacy (e.g., treatment of negative schizophrenic symptoms with risperidone). Risperidone 336-347 catechol-O-methyltransferase Homo sapiens 143-147 14610521-0 2003 Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Risperidone 68-79 catechol-O-methyltransferase Homo sapiens 28-32 29255361-0 2017 Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia. Risperidone 126-137 catechol-O-methyltransferase Homo sapiens 48-76 32572118-2 2020 The study assessed the association of the COMT rs4680 and rs4818 polymorphisms with therapeutic response to olanzapine, risperidone, clozapine or other antipsychotic medication after 8 weeks of monotherapy in patients with schizophrenia. Risperidone 120-131 catechol-O-methyltransferase Homo sapiens 42-46 29160620-5 2018 The COMT DNA methylation rate was lower in patients receiving atypical antipsychotics (P = 0.004) and risperidone (P = 0.049) as compared to typical antipsychotics. Risperidone 102-113 catechol-O-methyltransferase Homo sapiens 4-8 29255361-1 2017 Objective: The current study aimed to explore the association of single nucleotide polymorphisms (SNPs) within catechol-O-methyltransferase (COMT) and dopamine receptors with schizophrenia and genetic association with risperidone treatment response. Risperidone 218-229 catechol-O-methyltransferase Homo sapiens 111-139 29255361-1 2017 Objective: The current study aimed to explore the association of single nucleotide polymorphisms (SNPs) within catechol-O-methyltransferase (COMT) and dopamine receptors with schizophrenia and genetic association with risperidone treatment response. Risperidone 218-229 catechol-O-methyltransferase Homo sapiens 141-145 29255361-10 2017 SNPs (COMT rs165599 and DRD2 rs1801028) were significantly associated with risperidone efficacy on negative symptoms (P<0.05). Risperidone 75-86 catechol-O-methyltransferase Homo sapiens 6-10 29255361-11 2017 Conclusion: COMT SNPs and dopamine receptor SNPs were correlated with prevalence of schizophrenia and risperidone treatment efficacy of schizophrenia. Risperidone 102-113 catechol-O-methyltransferase Homo sapiens 12-16 26491028-9 2016 IL-6 levels significantly increased the risperidone-induced expression of AKT1, DICER1, DROSHA, and COMT mRNA. Risperidone 40-51 catechol-O-methyltransferase Homo sapiens 100-104 26491028-12 2016 Increased IL-6 levels may prime the expression of genes (AKT1, DICER1, DROSHA, and COMT) in response to risperidone, suggesting that cytokine x treatment x gene interactions may improve cell function profiles. Risperidone 104-115 catechol-O-methyltransferase Homo sapiens 83-87 22935916-0 2012 Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Risperidone 65-76 catechol-O-methyltransferase Homo sapiens 22-26 25042870-12 2014 CONCLUSIONS: Differences in the pharmacokinetics of risperidone are due to polymorphisms in CYP2D6, COMT, and VKORC1. Risperidone 52-63 catechol-O-methyltransferase Homo sapiens 100-104 22935916-3 2012 We genotyped 10 single-nucleotide polymorphisms (SNPs) of the catechol-O-methyl transferase gene (COMT) in our patients and re-examined them for association with changes in BPRS scores after 8 weeks of risperidone monotherapy. Risperidone 202-213 catechol-O-methyltransferase Homo sapiens 62-91 22935916-3 2012 We genotyped 10 single-nucleotide polymorphisms (SNPs) of the catechol-O-methyl transferase gene (COMT) in our patients and re-examined them for association with changes in BPRS scores after 8 weeks of risperidone monotherapy. Risperidone 202-213 catechol-O-methyltransferase Homo sapiens 98-102 22935916-6 2012 Our aim in this study was to explore the influence of COMT polymorphisms on pharmacological response to risperidone in the Chinese population. Risperidone 104-115 catechol-O-methyltransferase Homo sapiens 54-58 22935916-8 2012 The COMT gene polymorphism, SNP rs9606186, is associated with risperidone therapy efficiency in the Chinese population. Risperidone 62-73 catechol-O-methyltransferase Homo sapiens 4-8 22560999-0 2012 Impact of catechol-o-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. Risperidone 56-67 catechol-O-methyltransferase Homo sapiens 10-38 22560999-1 2012 OBJECTIVES: The main aim was to study the effects of COMT polymorphisms on response of risperidone treatment for schizophrenia and investigate the correlation between memory function of schizophrenia patients and COMT polymorphisms. Risperidone 87-98 catechol-O-methyltransferase Homo sapiens 53-57 22560999-8 2012 CONCLUSIONS: The COMT polymorphisms may be a potential biomarker for clinical risperidone treatment in schizophrenia. Risperidone 78-89 catechol-O-methyltransferase Homo sapiens 17-21 20053459-0 2010 Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia. Risperidone 79-90 catechol-O-methyltransferase Homo sapiens 15-43 20053459-0 2010 Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia. Risperidone 79-90 catechol-O-methyltransferase Homo sapiens 45-49 19451915-6 2009 The greater prevalence of poor-responder GRM3 and COMT alleles in white versus African-American patients might have a clinical significance in evaluating the ethnic-specific response to risperidone. Risperidone 186-197 catechol-O-methyltransferase Homo sapiens 50-54 19290789-9 2009 CONCLUSION: The present study thus indicates that the interacting effects within the COMT gene polymorphisms may influence the disease status and response to risperidone in schizophrenia patients. Risperidone 158-169 catechol-O-methyltransferase Homo sapiens 85-89